GC Cell Corporation (KOSDAQ:144510)

Market Cap	314.82B
Revenue (ttm)	174.45B
Net Income (ttm)	-73.90B
Shares Out	15.03M
EPS (ttm)	-4,918.00
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.48%)
Ex-Dividend Date	n/a

Volume	36,307
Average Volume	63,894
Open	21,250
Previous Close	21,350
Day's Range	20,850 - 21,800
52-Week Range	20,850 - 43,150
Beta	0.83
RSI	33.34
Earnings Date	May 9, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.